
Vyriad Launches Phase 1 Trial of VV169 In Vivo CAR T Cell Therapy After FDA IND Clearance
Vyriad Begins Phase 1 Clinical Trial for Lead In Vivo CAR T Cell Therapy VV169 Following FDA Acceptance of IND Application Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced that…













